The Chinese supervisory authority NMPA gave the green light for the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy and docetaxel, as Bayer announced in Berlin. Such an approval already exists for Nubeqa for Europe, the USA and Japan.
The number of prostate cancer cases in China has recently increased significantly, said Bayer oncology boss Christine Roth. Almost a third of newly diagnosed patients would have metastases. So far, Nubeqa has only been approved in China for the treatment of non-metastatic castration-resistant prostate cancer.
The relatively new drug was one of the 15 most important Bayer drugs in 2022 with sales of EUR 466 million. Bayer estimates annual peak sales at more than 3 billion euros. The active substance darolutamide is being developed jointly with the Finnish pharmaceutical company Orion.
In XETRA trading, Bayer shares temporarily rose by 0.59 percent to EUR 56.14.
FRANKFURT (Dow Jones)
Leverage must be between 2 and 20
No data
More news about Bayer
Image sources: Lukassek / Shutterstock.com, Arseniy Krasnevsky / Shutterstock